Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Discover more on how Polpharma API meets evolving regulatory guidance around N-nitrosamines control in APIs with Waters’ high-performance analysis instruments.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
Join this webinar to hear about the latest RMM technology and how it aligns with UPS testing criteria.
Webinar

The trend towards outsourced buffer manufacturing in biopharmaceuticals

9 May 2024

2:00pm

Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.

Secure your place now.

Buffers, the compounds or compound mixtures used to control pH in drug manufacturing, are a vital component to maintain the stability of both small molecule and biologic drugs during production and in their final form. Today, with rising interest in cell and gene therapies (CGTs) for diseases ranging from cancer to inherited diseases, and the growing need for the manufacturing of vaccines. Biopharmaceutical companies are increasingly looking to outsource the development and production of buffers for both their drug development programs and therapeutics manufacturing.

Whether constrained by physical space, requirements for higher titers, lack of resources, or a preference for lean operations, the economics of make-v-buy when it comes to buffers is leaning to buy. Growth in CGT, as well as changes in the small molecule market, have made the production and use of buffers more specialized and more challenging. As a result, large and small biopharmaceutical companies alike are increasingly relying on third parties to source their buffers.

 

Key learning points: 

  • The growth of the biopharma market
  • The challenges this growth brings
  • Why are companies outsourcing?
  • The benefits of outsourcing
  • Future development
     

Register your place now

OUR SPEAKER

Kate Buggle, Sales Director, Biopharma Europe

Kate Buggle is the Strategic Business Development Director for Actylis’ European Biopharmaceutical division. A biochemist educated at University College Dublin (BSc) and National University of Ireland, Galway (MSc), she has spent 20+ years in specialty chemicals and biopharmaceutical buffer sales, marketing, and customer support roles, including six years at Merck KGaA, Darmstadt, and 16 at SAFC. 

FAQs

FAQs

Is the webinar free? 

Yes – there is no charge to watch the webinar, either live or on-demand. 

When will the webinar take place? 

9 May 2024 at 3.00pm BST

Can I watch it later? 

The webinar will become available to watch on-demand shortly after the live webinar takes place. 

What are the benefits of attending live? 

You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session. 

How long will the webinar be? 

This webinar will last up to an hour. 

What do I need to watch this webinar? 

All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.